Scholar Rock Holding Advances Obesity Treatment with Promising SRK-439 Antimyostatin Antibody Findings

Scholar Rock Advances Muscle Health Research with Promising Antimyostatin Antibody Data

Scholar Rock Holding, a late-stage biopharmaceutical company based in Cambridge, Massachusetts, showcases significant advancements in its research on obesity treatment through the investigational antimyostatin antibody, SRK-439. The company plans to present preclinical findings at the upcoming ObesityWeek conference on November 5 in San Antonio, Texas. This research highlights the potential of SRK-439 to enhance lean mass and reduce fat mass gain, particularly when combined with metformin, a widely used medication for managing diabetes. The presentation by Dr. Melissa Fulham underscores Scholar Rock's commitment to addressing obesity and its related health conditions.

In a carefully designed study utilizing a murine model of diet-induced obesity, Scholar Rock demonstrates that SRK-439 could significantly improve body composition. The study involved mice placed on a high-fat diet, with one group receiving metformin alongside SRK-439, while another group received only metformin and an IgG control antibody. The results are compelling; young mice treated with SRK-439 show a two-fold increase in lean mass compared to their counterparts on metformin alone, with a lean mass increase of 31.6% versus 15.1% (p<0.0001). Older mice display even more impressive outcomes, with a 50-fold enhancement in lean mass when treated with SRK-439, indicating the antibody's substantial potential for promoting healthier body composition.

The implications of these findings extend beyond mere muscle gain, as they reinforce Scholar Rock's hypothesis that selective myostatin inhibition can be a key strategy in combating obesity and associated metabolic disorders. Jay Backstrom, the company's President and CEO, emphasizes the promise of these results in guiding future research and therapeutic approaches. Scholar Rock looks forward to further developments in its cardiometabolic program, with topline data from the ongoing Phase 2 EMBRAZE trial anticipated in the second quarter of 2025. This timeline reflects the company's dedication to advancing treatments that may revolutionize weight management strategies.

In addition to the promising results of SRK-439, Scholar Rock continues to position itself at the forefront of biopharmaceutical innovation, focusing on conditions with significant unmet medical needs. The company’s research into muscle health and metabolic disorders aligns with global trends emphasizing the importance of addressing obesity and its impacts on overall health. As the landscape of obesity treatment evolves, Scholar Rock is poised to contribute significantly with its targeted therapeutic approaches.